Study 45 – Randomized, Double-Blind, Placebo-Controlled Trial of Monthly Injectable Buprenorphine for Methamphetamine Use Disorder (MURB); CTN-0110

Principal Investigators: Steve Shoptaw, Ph.D. (University of California, Los Angeles), Madhukar H. Trivedi, M.D. (University of Texas Southwestern Medical Center)

Site Investigators: Erik Anderson, M.D., Andrew Herring, M.D. (Alameda Health System), Tara Chowdhury, Ph.D. (COGA, Inc.), Julie Croff, Ph.D., MPH, FAAHB (Oklahoma State University), Sidarth Wakhlu, M.D. (University of Texas Southwestern Medical Center), Judith Tsui, M.D. (University of Washington) Timothy Hall, M.D., Ph.D. (University of California, Los Angeles Vine Street Clinic)

Release Date: Closed

Description: The 4th wave of the opioid crisis involves increasing polydrug stimulant and opiate use. Incidence of overdose deaths due to polysubstance use involving opioids co-occurring with methamphetamine increased from 2017 to 2018 by 14.6%. According to the National Survey on Drug Use and Health in 2018, an estimated 1,867,000 of persons in US aged 12 years and older, reported methamphetamine use in the past year and 1,051 000 reported substance use disorder in the past year involving methamphetamines. There are no effective medications for treating methamphetamine use disorder. This proposal will test the superiority of long-acting buprenorphine (and its kappa antagonist activity) over placebo as a treatment for methamphetamine use disorder among persons who co-use opioids.


No instrument available